What does the acetyl group protect against?

Aminopeptidases attacking the N-terminus. It does not protect the C-terminus or block internal cleavage by endopeptidases.

Why not add albumin binding like semaglutide?

The fragment was made to study a motif rather than to function as a durable agent. Half-life extension is a deliberate engineering step that was never applied here.

TB-500 Half-Life and Why It Is Short

The short answer

TB-500 carries no half-life extension technology, no fatty acid, no albumin binding, no protease-resistant substitutions beyond N-terminal acetylation. A 889 Da peptide is small enough to be filtered renally and is exposed to peptidases, so clearance is rapid.

Key facts

Size: 889.0 Da. Freely filtered by the kidney
Half-life extension: None
Albumin binding: No fatty acid conjugate
N-terminal acetylation: Blocks aminopeptidases only
C-terminus: Unprotected
Endopeptidases: Unaffected by terminal capping

Two clearance routes, both open

A molecule this small passes the glomerulus unimpeded, the filtration barrier retains things around 60 kDa and above, and 889 Da is far below any threshold. Separately, peptidases in plasma and tissue cleave peptide bonds. Neither route is obstructed by anything in TB-500's structure.

What acetylation does and does not do

Aminopeptidases remove residues from a free N-terminus. Capping that terminus with an acetyl group blocks them, which is a real protective effect. It does nothing about carboxypeptidases attacking the other end, and nothing at all about endopeptidases cleaving internally. One of three routes closed is useful but not transformative.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The contrast with engineered peptides

Semaglutide illustrates what deliberate half-life extension looks like: an Aib substitution blocking DPP-4, plus a C18 diacid binding albumin so the complex is too large to filter and is physically shielded. That combination takes GLP-1 from one to two minutes to about a week. TB-500 has none of it, which is a design difference rather than an oversight. The fragment was made to study a motif, not to be a durable agent.

Why this matters for interpreting studies

A compound cleared rapidly reaches its target briefly, and effects observed in a study depend on the exposure the protocol produced. Comparing outcomes between studies using different administration schedules is comparing different exposures, not different potencies. This is the sort of detail that separates a mechanistic result from a practical one.

The full protein is different again

Thymosin beta-4 at 4,963 Da is still well below the renal filtration threshold, so it is not protected by size either, but its pharmacokinetics are not the fragment's, and studies using the protein should not be read as characterising the peptide.

Frequently asked questions

Does TB-500 have a long half-life?: No. At 889 Da with no albumin binding or protease-resistant substitutions beyond N-terminal acetylation, clearance is rapid.
What does the acetyl group protect against?: Aminopeptidases attacking the N-terminus. It does not protect the C-terminus or block internal cleavage by endopeptidases.
Why not add albumin binding like semaglutide?: The fragment was made to study a motif rather than to function as a durable agent. Half-life extension is a deliberate engineering step that was never applied here.

Extended research context

The TB-500 (Thymosin β4 fragment) deep dive

Deep dive: TB-500 vs full-length Thymosin Beta-4

'TB-500' is a synthetic peptide corresponding to the active 17-amino-acid actin-binding region of the endogenous 43-residue Thymosin Beta-4 protein. The two are not identical. TB-500 lacks the flanking sequence that gives full-length TB-4 additional binding partners. In the research literature, papers use 'Thymosin β4' when they mean the full protein and 'TB-500' or 'AcSDKP fragment' when they mean the shorter synthetic peptide. Reading a CoA carefully to see which molecule is in the vial matters. Mass spec is the definitive check.

Actin-binding as the core mechanism

The N-terminal region of TB-4 (and TB-500 by inheritance) contains the canonical actin-binding motif. This motif sequesters G-actin monomers, modulating the G:F actin equilibrium in cell cultures. That mechanism is why almost every mechanistic paper on TB-500 traces back to cytoskeletal reorganisation, cell migration, and models of tissue repair.

Handling considerations unique to TB-500

TB-500 is a 17-residue peptide with modest amphipathicity; it reconstitutes cleanly in bacteriostatic water but is sensitive to repeated freeze/thaw. Aliquoting into single-use volumes on first reconstitution preserves potency across a batch. HPLC on the batch CoA should show a single dominant peak; a doublet suggests deamidation.

Research applications

▸In vitro actin-polymerisation assays (G:F actin ratio measurement)
▸Cell-migration and wound-scratch assays in fibroblast lines
▸Angiogenesis models: tube-formation and endothelial migration assays
▸Analytical method development for short peptides on RP-HPLC
▸Reference-material comparisons against endogenous Thymosin β4

Handling checklist

✓Store lyophilised vials at −20 °C long-term
✓Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
✓Aliquot immediately to avoid freeze/thaw cycles
✓Refrigerate reconstituted aliquots at 2–8 °C; use within 28 days
✓Confirm mass (~4,963 Da for TB-500) via CoA before study use

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Assuming TB-500 = full Thymosin β4

Fix: TB-500 is the 17-residue actin-binding fragment; check the CoA sequence.

✗ Repeated freeze/thaw

Fix: Aliquot at first reconstitution; each cycle degrades yield.

✗ Using tap water

Fix: Use bacteriostatic or sterile water only.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More TB-500 (Thymosin β4 fragment) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

TB-500 Half-Life and Clearance